Chemotherapy-induced peripheral neuropathy: Current status and progress

• Published in: Gynecologic oncology Vol. 140; no. 1; pp. 176 - 183
• Main Authors: Brewer, Jamie R, Morrison, Gladys, Dolan, M. Eileen, Fleming, Gini F
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy; Hematology, Oncology and Palliative Medicine; Humans; Models, Neurological; Neural Stem Cells - pathology; Neurons - pathology; Neuropathy; Obstetrics and Gynecology; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - pathology; Peripheral Nervous System Diseases - therapy; Taxoids - administration & dosage; Taxoids - adverse effects; Toxicity; Toxicity; Chemotherapy; Neuropathy
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2015.11.011

Abstract As there are increasing numbers of cancer survivors, more attention is being paid to the long term unwanted effects patients may experience as a result of their treatment and the impact these side effects can have on their quality of life. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common long-term toxicities from chemotherapy. In this review we will briefly review the clinical presentation, evaluation and management of chemotherapy-induced peripheral neuropathy, with a focus on CIPN related to platinum and taxane agents. We will then discuss current clinical models of peripheral neuropathy and ongoing research to better understand CIPN and develop potential treatment options.